#1 Clinical Trials Search in Europe

Hepatic cancer – Diagnostics

Go back

Diagnosing hepatic cancer requires careful evaluation through multiple steps—from recognizing early warning signs to undergoing specialized tests that help doctors determine the best treatment approach. Understanding when to seek diagnostic evaluation and what tests are involved can help you feel more prepared if you or someone you care about is at risk for this serious condition.

Introduction: Who Should Undergo Diagnostics and When

Hepatic cancer, also known as liver cancer, often develops without causing noticeable symptoms in its earliest stages. This makes knowing when to seek diagnostic evaluation particularly important, especially if you belong to a group at higher risk for developing this disease.[1]

You should consider seeking diagnostic evaluation if you notice certain warning signs or if you have underlying conditions that increase your risk. Unfortunately, many people with liver cancer don’t experience symptoms until the disease has grown larger or spread. When symptoms do appear, they may include yellowing of your skin and the whites of your eyes (a condition called jaundice), unexplained weight loss, loss of appetite, nausea and vomiting, unusual tiredness, or a hard lump on the right side of your body just below your rib cage.[2][5]

If you have chronic hepatitis B or hepatitis C infection, you face significantly higher risk of developing liver cancer. More than 70% of liver cancer cases are associated with viral hepatitis infections. Similarly, if you have cirrhosis—severe scarring of the liver—your annual risk of developing liver cancer ranges from 2% to 4%. Other conditions that should prompt regular monitoring include metabolic dysfunction-associated steatotic liver disease (also known as fatty liver disease), heavy alcohol use over many years, obesity, type 2 diabetes, or inherited conditions like hemochromatosis.[4][5]

Because early-stage liver cancer rarely causes symptoms, people at high risk should undergo regular screening even when they feel perfectly healthy. If you have cirrhosis or chronic viral hepatitis, your healthcare provider may recommend surveillance testing every three to six months. This proactive approach helps catch liver cancer at a stage when treatment options are more effective.[4][13]

⚠️ Important

If you experience symptoms such as persistent abdominal discomfort, yellowing of your skin or eyes, unexplained weight loss, or unusual fatigue lasting more than two weeks, contact a healthcare provider for evaluation. While these symptoms can occur with many conditions that are less serious than cancer, only proper medical assessment can determine their cause.

Diagnostic Methods for Identifying Liver Cancer

Diagnosing liver cancer involves several different approaches that work together to confirm whether cancer is present, identify its type, and determine how far it has spread. Your healthcare provider will typically start with less invasive tests and move to more specific examinations based on initial findings.[3]

Physical Examination and Medical History

Your diagnostic journey usually begins with a thorough physical examination. Your doctor will ask about your symptoms, medical history, lifestyle factors like alcohol use or exposure to hepatitis viruses, and any family history of liver disease. During the physical exam, they will feel your abdomen to check for an enlarged liver, swelling, or lumps. They may also look for signs of jaundice or other indicators of liver problems.[3]

Blood Tests

Blood tests play an important role in evaluating liver health and detecting possible cancer. Your healthcare provider may order liver function tests to measure how well your liver is working by checking levels of certain enzymes and proteins in your blood. These tests can reveal whether your liver is damaged or not functioning properly, though they cannot definitively diagnose cancer on their own.[3][23]

Another blood test looks for a substance called alpha-fetoprotein (AFP). AFP levels can be elevated in people with liver cancer, though not everyone with liver cancer will have high AFP levels. Additionally, elevated AFP can occur in other liver conditions, so this test is used alongside other diagnostic methods rather than alone.[23]

Imaging Tests

Imaging tests create pictures of the inside of your body and are essential for detecting liver tumors. Several types of imaging studies are commonly used in liver cancer diagnosis:

Ultrasound uses sound waves to create images of your liver and is often one of the first imaging tests performed. It’s painless, doesn’t use radiation, and can help identify masses or abnormalities in the liver. Ultrasound is also commonly used as a screening tool for people at high risk of liver cancer.[3][11]

CT scans (computed tomography) provide detailed, cross-sectional images of your liver and surrounding organs. For liver cancer evaluation, you’ll typically receive a special type of CT scan called a triple-phase or multiphase contrast-enhanced CT scan. This involves receiving an injection of contrast dye through a vein, then taking images at different times as the dye moves through your liver’s blood vessels. This technique helps doctors see how blood flows through liver tissues and can distinguish between cancerous and non-cancerous growths. The CT scan also provides information about tumor size, location, and whether cancer has spread to nearby lymph nodes or other organs.[3][17][23]

MRI (magnetic resonance imaging) uses powerful magnets and radio waves instead of radiation to create very clear, detailed images of your liver’s internal structures. Like CT scans, MRI for liver cancer typically involves contrast enhancement—you receive an injection of a special contrast agent that helps distinguish normal liver tissue from tumors. MRI can be particularly useful in characterizing liver lesions and determining whether they are cancerous. Some healthcare providers prefer MRI over CT for certain patients, especially when evaluating smaller lesions.[3][11][17]

Both triple-phase CT scans and MRI scans can sometimes diagnose liver cancer without requiring a biopsy, especially in patients with cirrhosis who have lesions larger than 1 centimeter that show characteristic appearance patterns on these imaging studies. This happens because liver cancer has distinctive features in how it takes up and releases contrast dye compared to normal liver tissue.[11][17]

Angiography

Angiography is a specialized imaging test that examines blood vessels in and around your liver. During this procedure, a thin tube called a catheter is inserted into a blood vessel (usually in your groin) and guided to the liver’s arteries. Contrast dye is then injected, and X-rays are taken to show how blood flows through your liver. This test helps doctors see the blood supply to tumors and can be useful in planning certain treatments. However, it’s used less frequently now because advanced CT and MRI techniques can provide similar information without the need for inserting a catheter.[3]

Liver Biopsy

A biopsy involves removing a small sample of liver tissue so it can be examined under a microscope by a specialist called a pathologist. This examination can definitively confirm whether cancer cells are present and identify the specific type of liver cancer. However, liver cancer is unique among cancers because biopsy is not always necessary for diagnosis.[11][24]

Your healthcare team may decide that imaging studies provide enough information to diagnose liver cancer, especially if you have cirrhosis and imaging shows characteristic patterns. In fact, for many patients with cirrhosis who have liver lesions showing typical features of cancer on high-quality CT or MRI scans, treatment decisions can be made without performing a biopsy. This approach avoids potential biopsy complications, such as bleeding or the theoretical risk of spreading cancer cells along the needle track.[11][17]

When biopsy is needed—for example, when imaging results are unclear or when confirming diagnosis would significantly change treatment decisions—it’s typically performed as a needle biopsy. During this procedure, a thin needle is inserted through your skin and into the liver tumor while ultrasound or CT imaging guides its placement. You’ll receive local anesthesia to numb the area. The needle removes a tiny sample of tissue that is then analyzed in a laboratory.[24]

Additional Diagnostic Procedures

In some situations, your doctor may recommend additional tests to gather more information. ERCP (endoscopic retrograde cholangiopancreatography) is a procedure that combines endoscopy and X-rays to examine the bile ducts, which are tubes that carry bile from your liver to your intestine. This test may be performed if doctors suspect that cancer is affecting your bile ducts. During ERCP, a flexible tube with a camera is passed through your mouth, down your esophagus and stomach, and into the beginning of your small intestine where the bile ducts empty. Contrast dye is then injected into the bile ducts, and X-rays are taken.[3]

Lesions Smaller Than 1 Centimeter

If screening or imaging detects a lesion in your liver that measures less than 1 centimeter, most guidelines recommend close monitoring rather than immediate diagnostic procedures. Many of these small spots turn out to be non-cancerous. The typical approach is to repeat imaging every three months using the same technique that first identified the lesion. If the lesion grows or changes in appearance, further diagnostic evaluation will be performed. This cautious “watch-and-wait” strategy balances the need to detect cancer early against the recognition that most very small liver lesions in at-risk patients are not cancer.[17]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or new ways of using existing treatments. If you’re considering participating in a clinical trial for liver cancer, you’ll undergo specific tests to determine whether you qualify for the study. These qualification requirements exist to ensure participant safety and to create groups of patients whose results can be meaningfully compared.[4]

The diagnostic tests required for clinical trial enrollment typically include many of the same evaluations used in standard diagnosis, but they may be more extensive or need to meet specific criteria. Almost all liver cancer clinical trials will require confirmation of your diagnosis through imaging studies (CT scan, MRI, or both) and detailed documentation of the stage and extent of your cancer. This information helps researchers understand whether the treatment being studied is appropriate for your particular situation.[14]

Blood tests are nearly always required as part of clinical trial screening. These tests assess your liver function, kidney function, blood cell counts, and overall health status. Clinical trials often have specific requirements about liver function—for example, they may only accept participants whose liver is working well enough to process the study medication, or they may focus on people with more advanced liver disease. Your levels of various liver enzymes, bilirubin (a substance that causes jaundice when elevated), and albumin (a protein made by the liver) will be measured and compared against the trial’s eligibility criteria.[4][14]

Many clinical trials also evaluate your performance status—a measure of how well you’re able to carry out daily activities. Healthcare providers use standardized scales to rate your ability to care for yourself, work, and stay active. This assessment helps determine whether you’re healthy enough to tolerate the experimental treatment being studied.[14]

The stage of your cancer is another critical factor in clinical trial eligibility. Trials are often designed for specific stages of liver cancer. For instance, some trials enroll only patients with early-stage, resectable (removable by surgery) tumors, while others focus on advanced cancer that has spread beyond the liver. To determine your cancer stage, you may need imaging that evaluates not just your liver but also your chest, bones, and other organs to check whether cancer has spread.[14][17]

If the clinical trial involves testing a targeted therapy or immunotherapy—treatments that work on specific molecular features of cancer cells or immune system components—you may need additional specialized tests. These might include testing tumor tissue for particular genetic mutations, protein markers, or other biological characteristics. Some trials require a fresh biopsy sample obtained specifically for the study, even if you’ve had biopsies in the past, to ensure the tissue analysis meets the research protocol’s standards.[14][19]

For trials involving immunotherapy—treatments that help your immune system fight cancer—your history of certain conditions becomes particularly important. Because some people with liver cancer have a history of hepatitis virus infections, and because these viruses affect the immune system, clinical trials must carefully evaluate whether immunotherapy is safe for you. The presence or absence of active viral infection, and measures of your immune system function, may be assessed through blood tests.[7][19]

⚠️ Important

Clinical trial eligibility criteria can be quite specific, and not qualifying for one trial doesn’t mean you won’t qualify for others. If you’re interested in clinical trials, discuss this option with your healthcare team. They can help identify trials that might be appropriate for your situation and guide you through the screening process. Participating in a clinical trial not only gives you access to potentially promising new treatments but also contributes to advancing knowledge that may help future patients.

Documentation requirements for clinical trials are typically more rigorous than for standard care. You may need to provide detailed medical records, pathology reports from biopsies, and copies of imaging studies. Researchers need this comprehensive information to verify that you meet all the trial’s inclusion criteria and none of its exclusion criteria.[14]

Some clinical trials have restrictions based on previous treatments you’ve received. For example, certain trials are designed for people who have never received systemic treatment for liver cancer (first-line trials), while others are for people whose cancer has progressed despite previous treatment (second-line or later-line trials). The diagnostic process for trial enrollment will therefore include documenting your complete treatment history.[14][19]

Throughout your participation in a clinical trial, you’ll undergo regular monitoring through repeated blood tests, imaging studies, and physical examinations. These ongoing assessments serve both to monitor your health and safety and to measure how well the experimental treatment is working. The frequency and type of these monitoring tests are specified in the trial protocol.[14]

Prognosis and Survival Rate

Prognosis

The prognosis for people with hepatic cancer depends on several important factors, including the stage at which cancer is detected, how well the liver is functioning, and your overall health. Liver cancer is considered a serious and life-threatening condition, but outcomes vary widely depending on these circumstances.[3][13]

The stage of cancer at diagnosis is one of the most significant factors affecting prognosis. When liver cancer is found early and is small enough to be completely removed by surgery or treated with other local therapies like ablation, the chances of longer survival improve considerably. Unfortunately, because liver cancer often doesn’t cause symptoms in its early stages, many people are diagnosed when the disease is more advanced, which generally means fewer treatment options and a more challenging prognosis.[2][3]

How well your liver is working—called liver function—significantly impacts both your prognosis and which treatments you can safely receive. Many people with liver cancer also have cirrhosis or other forms of chronic liver disease. When the liver is severely damaged, it cannot perform its vital functions effectively, which limits treatment options and affects overall outcomes. Doctors use various measures to assess liver function, and this assessment helps guide treatment decisions and provides information about likely outcomes.[13][25]

The specific type of liver cancer also matters. Hepatocellular carcinoma accounts for about 85% to 90% of primary liver cancers. Within this category, some tumors grow more aggressively than others. Another type called cholangiocarcinoma, which starts in the bile ducts, tends to have a particularly challenging prognosis with a five-year survival rate of approximately 2%.[7][8]

Your age, overall health, and the presence of other medical conditions also influence prognosis. People who are otherwise healthy may tolerate treatments better and have better outcomes than those with multiple health problems. Additionally, factors like your nutritional status and whether you’re able to remain physically active can affect how well you respond to treatment and your quality of life during treatment.[13]

Survival Rate

Survival rates provide statistical estimates of what percentage of people with a particular cancer are still alive after a certain period—usually measured at five years after diagnosis. For liver cancer, the overall five-year survival rate is approximately 17% to 18%. This means that, on average, about 17 to 18 out of every 100 people diagnosed with liver cancer will be alive five years after their diagnosis. However, it’s crucial to understand that survival rates vary dramatically depending on the stage at diagnosis.[7][23]

When liver cancer is caught at a localized stage—meaning it’s found early and hasn’t spread beyond the liver—the five-year survival rate is around 31%. This higher rate reflects the fact that localized cancer can potentially be treated with curative approaches like surgery or liver transplantation. However, fewer than half of liver cancer cases are diagnosed at this early, localized stage because symptoms often don’t appear until the cancer has grown or spread.[23]

For people diagnosed with regional liver cancer—cancer that has spread to nearby lymph nodes or structures but hasn’t reached distant organs—the five-year survival rate drops to approximately 11%. When liver cancer has spread to distant parts of the body (called metastatic cancer), the five-year survival rate is about 3%.[23]

These statistics represent averages across large groups of people and include individuals diagnosed several years ago whose treatments may differ from what’s available today. Your personal outlook depends on your specific circumstances, including factors that statistics cannot fully capture. Some people do much better than average, while others face more challenging outcomes. New treatments, particularly immunotherapies and targeted therapies, are being developed and may improve survival rates in the future, though their long-term effects are still being studied.[19][23]

For people with hepatocellular carcinoma specifically, survival also relates to whether they have cirrhosis. Among patients with cirrhosis, the annual incidence of developing liver cancer ranges from 2% to 4%, and hepatocellular carcinoma occurs in approximately 80% to 90% of people who have cirrhosis. The presence of cirrhosis not only increases cancer risk but also affects treatment options and prognosis because a badly scarred liver functions less effectively.[4][13]

Ongoing Clinical Trials on Hepatic cancer

  • Study of intra-arterial angiotensin II during radioembolization to improve treatment effectiveness in patients with primary or secondary liver cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Evaluating the use of technetium (99mTc) galactosyl serum albumin to predict complications in patients undergoing surgery for liver tumors

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Denmark

  • Study of Cobolimab and Dostarlimab for Children and Young Adults with Newly Diagnosed or Relapsed/Refractory Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy Spain

  • Study of Pembrolizumab and Lenvatinib for Patients with Advanced Liver Cancer Resistant to Previous Immunotherapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

References

https://www.mayoclinic.org/diseases-conditions/liver-cancer/symptoms-causes/syc-20353659

https://www.cancer.gov/types/liver/what-is-liver-cancer

https://my.clevelandclinic.org/health/diseases/9418-liver-cancer

https://www.ncbi.nlm.nih.gov/books/NBK559177/

https://www.cdc.gov/liver-cancer/about/index.html

https://www.cancer.org.au/cancer-information/types-of-cancer/liver-cancer

https://www.cancerresearch.org/blog/5-things-you-need-to-know-about-liver-cancer-2

https://www.cancer.org/cancer/types/liver-cancer/about/what-is-liver-cancer.html

https://www.cancerresearchuk.org/about-cancer/liver-cancer

https://www.mcw.edu/departments/surgery/divisions/surgical-oncology/patient-care/liver-pancreas-and-bile-duct-programs-hpb/liver-cancer/basic-information-on-liver-cancer

https://www.mayoclinic.org/diseases-conditions/liver-cancer/diagnosis-treatment/drc-20353664

https://www.cancer.org/cancer/types/liver-cancer/treating.html

https://my.clevelandclinic.org/health/diseases/21709-hepatocellular-carcinoma-hcc

https://www.cancer.gov/types/liver/what-is-liver-cancer/treatment

https://www.mdanderson.org/cancer-types/liver-cancer/liver-cancer-treatment.html

https://cancer.ca/en/cancer-information/cancer-types/liver/treatment

https://www.ncbi.nlm.nih.gov/books/NBK66030/

https://www.nhs.uk/conditions/liver-cancer/treatment/

https://www.cancerresearch.org/immunotherapy-by-cancer-type/liver-cancer

https://www.cancer.org/cancer/types/liver-cancer/after-treatment/follow-up.html

https://www.cancercare.org/publications/238-coping_with_liver_cancer

https://www.onelivertolove.com/living-healthy-liver-cancer

https://www.cancerresearch.org/blog/5-things-you-need-to-know-about-liver-cancer-2

https://www.mayoclinic.org/diseases-conditions/liver-cancer/diagnosis-treatment/drc-20353664

https://liverfoundation.org/liver-diseases/cancer/hepatocellular-carcinoma/

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://pmc.ncbi.nlm.nih.gov/articles/PMC6558629/

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

More information about
Hepatic cancer:

FAQ

Can liver cancer be detected through routine blood work?

Blood tests alone cannot definitively diagnose liver cancer, but they can provide important clues. Tests measuring liver function and a substance called alpha-fetoprotein (AFP) may suggest liver cancer, but imaging studies like ultrasound, CT scans, or MRI are needed to confirm the diagnosis. Blood tests are helpful for monitoring people at high risk and for assessing liver health, but they work best when combined with other diagnostic methods.

Why don’t all liver cancer patients need a biopsy?

Liver cancer has distinctive features on advanced imaging scans that can reliably confirm diagnosis without tissue sampling, especially in people with cirrhosis. High-quality CT or MRI scans showing characteristic patterns of how tumors take up contrast dye can provide enough information to make treatment decisions. Avoiding biopsy when possible eliminates the small risks associated with the procedure, such as bleeding or spreading cancer cells along the needle track.

How often should I be screened if I have hepatitis or cirrhosis?

If you have chronic hepatitis B or C infection, or cirrhosis from any cause, healthcare providers typically recommend screening every three to six months. This regular monitoring uses imaging tests, usually ultrasound, to detect liver cancer at its earliest and most treatable stage. Your healthcare provider will create a personalized screening schedule based on your specific risk factors and liver health.

What’s the difference between a CT scan and an MRI for diagnosing liver cancer?

Both CT scans and MRI create detailed images of your liver but use different technologies. CT scans use X-rays and are faster to perform, while MRI uses powerful magnets and radio waves without radiation exposure. For liver cancer diagnosis, both typically involve contrast enhancement—injection of special dye—to show how blood flows through liver tissue. MRI often provides slightly more detailed images and may be better for characterizing smaller lesions, but CT scans are excellent diagnostic tools as well. Your doctor will choose based on your specific situation and what’s available at your facility.

Do I need special preparation before liver cancer diagnostic tests?

Preparation requirements depend on which tests you’re having. For ultrasound, you may need to fast for several hours beforehand. CT and MRI scans with contrast require you to avoid eating and drinking for a period before the test, and your kidney function will be checked beforehand since the contrast dye is processed through your kidneys. For blood tests, fasting is sometimes required depending on what’s being measured. Your healthcare team will provide specific instructions for each test you’re scheduled to have.

🎯 Key Takeaways

  • • Most liver cancer develops silently without early symptoms, making regular screening critical for people with hepatitis infections, cirrhosis, or other risk factors.
  • • Liver cancer is one of the few cancers that can be diagnosed reliably through imaging alone, without always requiring a biopsy—advanced CT or MRI scans showing characteristic patterns may be sufficient.
  • • Viral hepatitis causes more than 70% of liver cancer cases worldwide, with hepatitis B and C being the primary culprits—vaccination for hepatitis B was the first cancer-prevention vaccine developed.
  • • Tiny liver lesions under 1 centimeter discovered during screening typically don’t need immediate invasive testing—doctors monitor them every three months since most prove to be non-cancerous.
  • • The stage at diagnosis dramatically affects survival—localized liver cancer has a 31% five-year survival rate compared to just 3% for cancer that has spread to distant organs.
  • • Clinical trials for liver cancer require comprehensive diagnostic workups including detailed imaging, blood tests measuring liver function, documentation of cancer stage, and sometimes special molecular testing of tumor tissue.
  • • Geographic differences exist in liver cancer rates within the United States, with the highest rates occurring in the southern and western coastal regions, and rates in men are more than double those in women.
  • • Annual risk of developing liver cancer among people with cirrhosis ranges from 2% to 4%, making surveillance imaging every few months a life-saving strategy for early detection.

Connected medications: